Publications
Although autoimmune bullous diseases are rare, they have generated many international research and study papers and guidelines. The following represent some of the most frequently mentioned by patients. It is not an exhaustive list by any means. We recommend you investigate further. Please let us know if you think there are any notable absences that we should include.
NHS guidelines
NHS Referral guidelines for specialist care
Publication
Rituximab trials
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial
Publication
UK commisioning policies
Clinical Commissioning Policy for the use of Rituximab in immunobullous disease (England)
Publication
Rituximab use
Rituximab for the treatment of pemphigus and pemphigoid disease in adults and children (OW10)
(All Wales Therapeutics and Toxicology Centre)
Publication
Treatments
Doxycycline: a first-line treatment for bullous pemphigoid? And Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial
Publication
Clinical consensus
The First International Consensus on Mucous Membrane Pemphigoid - Definition, Diagnostic Criteria, Pathogenic Factors, Medical Treatment, and Prognostic Indicators
Publication
Research priorities
The top 10 research priorities for the treatment of bullous pemphigoid, mucous membrane pemphigoid and pemphigus vulgaris in the UK: results of a James Lind Alliance Priority Setting Partnership
Publication
FDA patient perspectives
The Importance of Patient-Focused Drug Development in Pemphigus and Pemphigoid
Publication